Author

Juan J Pérez-Guerrero

Janssen Research & Development - Cited by 4,911 - Clinical Pharmacology - Pharmacometrics - Drug Development

Biography

Dr. Juan J Pérez-Guerrero is a versatile writer and scientist that published extensively in Infectious disease. He is affiliated to the Department of Clinical Pediatrics, Hospital Universitario Puerta del Mar, Cádiz, Spain.
Title
Cited by
Year
Population pharmacokinetics of esketamine nasal spray and its metabolite noresketamine in healthy subjects and patients with treatment-resistant depression
C Perez-Ruixo, S Rossenu, P Zannikos, P Nandy, J Singh, WC Drevets, ...Clinical Pharmacokinetics 60, 501-516, 2021202
30
2021
SARS-CoV-2 binding and neutralizing antibody levels after Ad26. COV2. S vaccination predict durable protection in rhesus macaques
R Roozendaal, L Solforosi, DJ Stieh, J Serroyen, R Straetemans, A Dari, ...Nature Communications 12 (1), 5877, 2021202
29
2021
Influence of disease and patient characteristics on daratumumab exposure and clinical outcomes in relapsed or refractory multiple myeloma
X Yan, PL Clemens, T Puchalski, S Lonial, H Lokhorst, PM Voorhees, ...Clinical pharmacokinetics 57, 529-538, 2018201
25
2018
Pharmacokinetic–pharmacodynamic modelling of neutrophil response to G‐CSF in healthy subjects and patients with chemotherapy‐induced neutropenia
M Melhem, I Delor, JJ Pérez‐Ruixo, J Harrold, A Chow, L Wu, P JacqminBritish Journal of Clinical Pharmacology 84 (5), 911-925, 2018201
23
2018
Efficacy and safety exposure-response relationships of apalutamide in patients with non-metastatic castration-resistant prostate cancer
C Perez-Ruixo, O Ackaert, D Ouellet, C Chien, H Uemura, D Olmos, ...Clinical Cancer Research, 2020202
11
2020
Population Pharmacokinetics of Apalutamide and its Active Metabolite N-Desmethyl-Apalutamide in Healthy and Castration-Resistant Prostate Cancer Subjects
C Perez-Ruixo, JS Perez-Blanco, C Chien, M Yu, D Ouellet, ...Clinical Pharmacokinetics 59, 229-244, 2020202
11
2020
Relating nicotine plasma concentration to momentary craving across four nicotine replacement therapy formulations
E Germovsek, A Hansson, MC Kjellsson, JJ Perez Ruixo, Å Westin, ...Clinical Pharmacology & Therapeutics 107 (1), 238-245, 202010202
10
2020
Clopidogrel, a CYP2C8 inhibitor, causes a clinically relevant increase in the systemic exposure to the active metabolite of selexipag in healthy subjects
Clopidogrel, a CYP2C inhibitor, causes a clinically relevant increase in the systemic exposure to the active metabolite of selexipag in healthy subjectsLN Axelsen, I Poggesi, F Rasschaert, JJ Perez Ruixo, S BrudererBritish journal of clinical pharmacology 7 (1), 119-12, 2021202
8
2021
Population pharmacokinetics of the rilpivirine long-acting formulation after intramuscular dosing in healthy subjects and people living with HIV
M Neyens, HM Crauwels, JJ Perez-Ruixo, S RossenuJournal of Antimicrobial Chemotherapy 6 (12), 3255-3262, 2021202
7
2021
Nicotine population pharmacokinetics in healthy smokers after intravenous, oral, buccal and transdermal administration
PO Olsson Gisleskog, JJ Perez Ruixo, Å Westin, AC Hansson, PA SoonsClinical Pharmacokinetics 60, 541-561, 2021202
7
2021
Prediction of survival benefit of filgrastim in adult and pediatric patients with acute radiation syndrome
J Harrold, PO Gisleskog, JJ Perez‐Ruixo, I Delor, A Chow, P Jacqmin, ...Clinical and translational science 13 (4), 807-817, 2020202
6
2020
Dose correction for a Michaelis–Menten approximation of a target-mediated drug disposition model with a multiple intravenous dosing regimens
X Yan, JJP Ruixo, W KrzyzanskiThe AAPS Journal 22, 1-15, 2020202
6
2020
Assessment of the effect of erdafitinib on cardiac safety: analysis of ECGs and exposure–QTc in patients with advanced or refractory solid tumors
E Valade, AG Dosne, H Xie, R Kleiman, LY Li, JJ Perez-Ruixo, D OuelletCancer Chemotherapy and Pharmacology 84, 21-33, 2019201
6
2019
Quantification of radiation injury on neutropenia and the link between absolute neutrophil count time course and overall survival in nonhuman primates treated with G-CSF
J Harrold, PO Gisleskog, I Delor, P Jacqmin, JJ Perez-Ruixo, ...Pharmaceutical Research 37, 1-11, 20205202
5
2020
Population Pharmacokinetics of Total and Free Erdafitinib in Adult Healthy Volunteers and Cancer Patients: Analysis of Phase 1 and Phase 2 Studies
AG Dosne, E Valade, K Stuyckens, LY Li, D Ouellet, JJ Perez‐RuixoThe Journal of Clinical Pharmacology, 2019201
5
2019
Receiver Operating Characteristic Analysis and Clinical Trial Simulation to Inform Dose Titration Decisions
JD Clements, JJ Perez Ruixo, JP Gibbs, S Doshi, C Perez Ruixo, ...CPT: Pharmacometrics & Systems Pharmacology 7 (11), 771-779, 2018201
4
2018
An Exposure-Response Analysis of the Clinical Efficacy of Ponesimod in a Randomized Phase II Study in Patients with Multiple Sclerosis
PO Gisleskog, B Valenzuela, T Scherz, M Burcklen, JJ Pérez-Ruixo, ...Clinical pharmacokinetics 60 (9), 1227-1237, 2021202
4
2021
Effect of Ponesimod Exposure on Total Lymphocyte Dynamics in Patients with Multiple Sclerosis
B Valenzuela, JJ Pérez-Ruixo, Q Leirens, S Ouwerkerk-Mahadevan, ...Clinical pharmacokinetics 60 (9), 129-1250, 2021202
3
2021
A translational model-based approach to inform the choice of the dose in phase 1 oncology trials: the case study of erdafitinib
EM Tosca, N Terranova, K Stuyckens, AG Dosne, T Perera, J Vialard, ...Cancer chemotherapy and pharmacology 89 (1), 117-128, 2022202
3
2022
Erdafitinib’s effect on serum phosphate justifies its pharmacodynamically guided dosing in patients with cancer
AG Dosne, E Valade, K Stuyckens, P De Porre, A Avadhani, A O’Hagan, ...CPT: Pharmacometrics & Systems Pharmacology 11 (5), 569-580, 2022202
3
2022

Referred From: https://scholar.google.es/citations?user=LOuWOgkAAAAJ&hl=es

Cited by
Citations 4911
h-index 34
i10-index 80
Recommended Journals
Open Access Journals